United Therapeutics Remodulin
FDA's Cardiovascular & Renal Drugs Advisory Committee will review the Remodulin NDA (21-272) for treatment of pulmonary hypertension during the morning of Aug. 9. The firm anticipates action on the application shortly following the meeting (1"The Pink Sheet" July 2, p. 18)
You may also be interested in...
FDA action on United Therapeutics' NDA for Remodulin in the treatment of pulmonary arterial hypertension therapy is expected soon after an Aug. 9 review by FDA's Cardiovascular & Renal Drugs Advisory Committee.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials